【开放获取】度普利尤单抗治疗特应性皮炎专家共识

doi:10.35541/cjd.20210885

Abstract

Abstract: 【Abstract】 Atopic dermatitis is a chronic inflammatory skin disease, characterized by eczematous dermatitis and severe pruritus, and has severe impact on patients′ quality of life. Patients with moderate to severe atopic dermatitis often require systemic treatments, but traditional systemic treatments are ineffective or intolerable in some patients. In recent years, several biological agents have been applied to the treatment of atopic dermatitis in clinical practice, among which the interleukin-4 receptor antagonist dupilumab has been marketed in China. Some experts in related fields from Working Group for Atopic Dermatitis, Chinese Society of Dermatology and Working Group for Children′s Diseases, Chinese Society of Dermatology discussed the application of dupilumab in the treatment of moderate to severe atopic dermatitis, and developed a consensus, in the hope of providing a reference for the clinical application of dupilumab in the treatment of atopic dermatitis.

Key words: Dermatitis, atopic, Therapy, Biological agents, Receptors, interleukin-4, Type 2 inflammation, Dupilumab

Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus[J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.doi:10.35541/cjd.20210885

References ［66］

［1］	Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey［J］. Allergy, 2018,73（6）:1284⁃1293. doi: 10.1111/all.13401.
［2］	顾恒, 尤立平, 刘永生, 等. 我国10城市学龄前儿童特应性皮炎现况调查［J］. 中华皮肤科杂志, 2004,37（1）:29⁃31. doi: 10.3760/j.issn:0412⁃4030.2004.01.011.
［3］	Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1⁃7 ys［J］. Sci Rep, 2016,6:29751. doi: 10.1038/srep29751.
［4］	Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis［J］. Clin Dermatol, 2018,36（5）:595⁃605. doi: 10.1016/j.clindermatol.2018.05.007.
［5］	Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies［J］. Allergol Int, 2017,66（3）:398⁃403. doi: 10.1016/j.alit.2016.12.002.
［6］	Dainichi T, Kitoh A, Otsuka A, et al. The epithelial immune microenvironment （EIME） in atopic dermatitis and psoriasis［J］. Nat Immunol, 2018,19（12）:1286⁃1298. doi: 10.1038/s41590⁃ 018⁃0256⁃2.
［7］	Yosipovitch G, Berger T, Fassett MS. Neuroimmune interactions in chronic itch of atopic dermatitis［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:239⁃250. doi: 10.1111/jdv.15973.
［8］	Davidson WF, Leung D, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on "Atopic dermatitis and the atopic march: mechanisms and interventions"［J］. J Allergy Clin Immunol, 2019,143（3）:894⁃913. doi: 10.1016/j.jaci.2019.01.003.
［9］	Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,143（1）:26⁃35. doi: 10.1016/j.jaci.2018.11.015.
［10］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［11］	吕婷, 王宏伟. 老年特应性皮炎的认识和管理［J］. 中国皮肤性病学杂志, 2019,33（8）:949⁃954. doi: 10.13735/j.cjdv.1001⁃7089.201810075.
［12］	Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta⁃analysis［J］. Curr Opin Allergy Clin Immunol, 2015,15（5）:453⁃460. doi: 10.1097/ACI. 0000000000000198.
［13］	Ravnborg N, Ambikaibalan D, Agnihotri G, et al. Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（2）:471⁃478. doi: 10.1016/j.jaad.2020.02.055.
［14］	Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Allergy Asthma Immunol, 2021,127（1）:49⁃56.e1. doi: 10.1016/j.anai.2021.02.026.
［15］	Silverberg JI. Comorbidities and the impact of atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2019,123（2）:144⁃151. doi: 10.1016/j.anai.2019.04.020.
［16］	Xu YC, Wang JP, Zhu WJ, et al. Childhood atopic dermatitis as a precursor for developing attention deficit/hyperactivity disorder［J］. Int J Immunopathol Pharmacol, 2020,34:2058 73842096 2902. doi: 10.1177/2058738420962902.
［17］	Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis［J］. Chin Med J （Engl）, 2016,129（7）:757⁃762. doi: 10.4103/0366⁃6999.178960.
［18］	Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China［J］. J Eur Acad Dermatol Venereol, 2020,34（3）:542⁃548. doi: 10.1111/jdv.15979.
［19］	Leshem YA, Hajar T, Hanifin JM, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study［J］. Br J Dermatol, 2015,172（5）:1353⁃1357. doi: 10.1111/bjd.13662.
［20］	Silverberg JI, Lei D, Yousaf M, et al. Comparison of Patient⁃Oriented Eczema Measure and Patient⁃Oriented Scoring Atopic Dermatitis vs Eczema Area and Severity Index and other measures of atopic dermatitis: a validation study［J］. Ann Allergy Asthma Immunol, 2020,125（1）:78⁃83. doi: 10.1016/j.anai.2020.03.006.
［21］	Silverberg JI, Margolis DJ, Boguniewicz M, et al. Validation of five patient⁃reported outcomes for atopic dermatitis severity in adults［J］. Br J Dermatol, 2020,182（1）:104⁃111. doi: 10.1111/bjd.18002.
［22］	Kido⁃Nakahara M, Yokote G, Yoshida M, et al. Atopic Dermatitis Control Tool （ADCT）: a useful tool for self⁃evaluation in patients with atopic dermatitis［J］. J Dermatol, 2021,48（12）:1951⁃1952. doi: 10.1111/1346⁃8138.16176.
［23］	US Food and Drug Administration. DUPIXENT （dupilumab） Prescribing Information［DB/OL］. ［2022⁃05⁃22］. https://www.regeneron.com/downloads/dupixent_fpi.pdf.
［24］	Lee JH, Kim JE, Park GH, et al. Consensus update for systemic treatment of atopic dermatitis［J］. Ann Dermatol, 2021,33（6）:497⁃514. doi: 10.5021/ad.2021.33.6.497.
［25］	Paller AS, Simpson EL, Siegfried EC, et al. Efficacy and safety of dupilumab in children aged ≥6 months to ＜6 years with moderate⁃to⁃severe atopic dermatitis［C/OL］//3rd Annual Revolutionizing Atopic Dermatits Conference （RAD 2021）, 2021［2022⁃05⁃12］. https://djbpnesxepydt.cloudfront.net/radv/December2021/690_Abstract_AD⁃1539⁃Part⁃B_Primary_Paller⁃et⁃al_1639409383487.pdf.
［26］	Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS［J］. J Am Acad Dermatol, 2020,82（6）:1328⁃1336. doi: 10.1016/j.jaad.2020.02.060.
［27］	Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open⁃label study of single⁃dose dupilumab in children aged 6 months to < 6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy［J］. J Eur Acad Dermatol Venereol, 2021,35（2）:464⁃475. doi: 10.1111/jdv.16928.
［28］	Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020.
［29］	Zhao Y, Wu L, Lu Q, et al. The efficacy and safety of dupilumab in Chinese patients with moderate⁃to⁃severe atopic dermatitis: a randomized, double⁃blind, placebo⁃controlled study［J］. Br J Dermatol, 2022,186（4）:633⁃641. doi: 10.1111/bjd.20690.
［30］	Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial［J］. JAMA Dermatol, 2020,156（1）:44⁃56. doi: 10.1001/jamadermatol.2019.3336.
［31］	Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate⁃to⁃severe atopic dermatitis: results from a phase Ⅱa open⁃label trial and subsequent phase Ⅲ open⁃label extension［J］. Br J Dermatol, 2020,182（1）:85⁃96. doi: 10.1111/bjd.18476.
［32］	Blauvelt A, de Bruin⁃Weller M, Gooderham M, et al. Long⁃term management of moderate⁃to⁃severe atopic dermatitis with dupilumab and concomitant topical corticosteroids （LIBERTY AD CHRONOS）: a 1⁃year, randomised, double⁃blinded, placebo⁃controlled, phase 3 trial［J］. Lancet, 2017,389（10086）:2287⁃2303. doi: 10.1016/S0140⁃6736（17）31191⁃1.
［33］	Li Y, Lu J, Chen R, et al. The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: a single⁃center retrospective study［J］. Dermatol Ther, 2022,35（5）:e15385. doi: 10.1111/dth.15385.
［34］	Gu C, Wu Y, Luo Y, et al. Real⁃world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single⁃centre, prospective, open⁃label study［J/OL］. J Eur Acad Dermatol Venereol, 2022. （2022⁃03⁃28）［2022⁃05⁃23］. https://onlinelibrary.wiley.com/doi/10.1111/jdv.18109. doi: 10.1111/jdv.18109.
［35］	Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double⁃blinded, placebo⁃controlled phase 3 trial［J］. J Am Acad Dermatol, 2020,83（5）:1282⁃1293. doi: 10.1016/j.jaad.2020.06. 054.
［36］	田晶, 梁源, 申春平, 等. 儿童中重度特应性皮炎首次皮下注射度普利尤单抗短期疗效和安全性分析［J］. 中华皮肤科杂志, 2022,55（4）:299⁃303. doi: 10.35541/cjd.20210734.
［37］	Lobo Y, Lee RC, Spelman L. Atopic dermatitis treated safely with dupilumab during pregnancy: a case report and review of the literature［J］. Case Rep Dermatol, 2021,13（2）:248⁃256. doi: 10.1159/000515246.
［38］	Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real⁃life study［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:958⁃964. doi: 10.1111/jdv.17094.
［39］	Patruno C, Fabbrocini G, Longo G, et al. Effectiveness and safety of long⁃term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real⁃life observational study［J］. Am J Clin Dermatol, 2021,22（4）:581⁃586. doi: 10. 1007/s40257⁃021⁃00597⁃5.
［40］	Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta⁃analysis of randomized controlled trials［J］. J Am Acad Dermatol, 2018,78（1）:62⁃69.e1. doi: 10.1016/j.jaad.2017.09.052.
［41］	Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis［J］. Am J Clin Dermatol, 2019,20（3）:443⁃456. doi: 10.1007/s40257⁃019⁃00445⁃7.
［42］	Sklover L, Nielson C, De Benedetto A. The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: case report［J］. Dermatol Ther, 2019,32（6）:e13144. doi: 10.1111/dth.13144.
［43］	Ludriksone L, Elsner P, Malessa C, et al. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report［J］. J Dtsch Dermatol Ges, 2020,18（7）:740⁃742. doi: 10.1111/ddg.14074.
［44］	Avallone G, Trunfio M, Giura MT, et al. Dupilumab in HIV⁃positive patients with atopic dermatitis: a long⁃term follow⁃up patient and a literature review［J］. Dermatol Online J, 2021,27（8）. doi: 10.5070/D327854709.
［45］	Ly K, Smith MP, Thibodeaux Q, et al. Dupilumab in patients with chronic hepatitis B on concomitant entecavir［J］. JAAD Case Rep, 2019,5（7）:624⁃626. doi: 10.1016/j.jdcr.2019.05.007.
［46］	Nakanishi M, Oota E, Tomita Y, et al. A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab［J］. J Dermatolog Treat, 2019,30（7）:674⁃676. doi: 10.1080/09546634.2019.1568379.
［47］	Goto H, Moriki M, Sano Y, et al. Successful preoperative intervention of dupilumab in high⁃risk surgery in a patient with severe atopic dermatitis［J］. J Dermatol, 2020,47（2）:e50⁃e51. doi: 10.1111/1346⁃8138.15187.
［48］	Fowler E, Rosen J, Lev⁃Tov H, et al. Two cancer patients receiving dupilumab for treatment of atopic dermatitis［J］. Acta Derm Venereol, 2019,99（10）:899⁃900. doi: 10.2340/00015555⁃3201.
［49］	Qiu Y, Ali K, Lou H, et al. Successful treatment of atopic dermatitis with dupilumab in a patient with non⁃Hodgkin′s lymphoma［J］. Acta Derm Venereol, 2022,102:adv00625. doi: 10.2340/actadv.v101.224.
［50］	Francuzik W, Alexiou A, Worm M. Safety of dupilumab in patients with atopic dermatitis: expert opinion［J］. Expert Opin Drug Saf, 2021,20（9）:997⁃1004. doi: 10.1080/14740338.2021. 1939673.
［51］	Miyashiro D, Vivarelli AG, Gonçalves F, et al. Progression of mycosis fungoides after treatment with dupilumab: a case report［J］. Dermatol Ther, 2020,33（6）:e13880. doi: 10.1111/dth.13880.
［52］	Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T⁃cell lymphoma after dupilumab: case review of 7 patients［J］. J Am Acad Dermatol， 2020,83（1）:197⁃199. doi: 10.1016/j.jaad.2020.03.050.
［53］	Poyner E, Bacon CM, Osborne W, et al. Dupilumab unmasking cutaneous T⁃cell lymphoma: report of a fatal case［J］. Clin Exp Dermatol, 2022,47（5）:974⁃976. doi: 10.1111/ced.15079.
［54］	Nettis E, Fabbrocini G, Ortoncelli M, et al. Long⁃term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients［J］. Br J Dermatol, 2021,184（3）:561⁃563. doi: 10.1111/bjd.19577.
［55］	Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial［J］. JAMA Dermatol, 2020,156（2）:131⁃143. doi: 10.1001/jamadermatol.2019.3617.
［56］	Halling AS, Loft N, Silverberg JI, et al. Real⁃world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（1）:139⁃147. doi: 10.1016/j.jaad.2020.08.051.
［57］	Akinlade B, Guttman⁃Yassky E, de Bruin⁃Weller M, et al. Conjunctivitis in dupilumab clinical trials［J］. Br J Dermatol, 2019,181（3）:459⁃473. doi: 10.1111/bjd.17869.
［58］	Ou Z, Chen C, Chen A, et al. Adverse events of Dupilumab in adults with moderate⁃to⁃severe atopic dermatitis: a meta⁃analysis［J］. Int Immunopharmacol, 2018,54:303⁃310. doi: 10.1016/j.intimp.2017.11.031.
［59］	Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate⁃to⁃severe atopic dermatitis: results from three phase Ⅲ trials （LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS）［J］. Br J Dermatol, 2020,182（5）:1120⁃1135. doi: 10.1111/bjd.18434.
［60］	Zirwas MJ, Wulff K, Beckman K. Lifitegrast add⁃on treatment for dupilumab⁃induced ocular surface disease （DIOSD）: a novel case report［J］. JAAD Case Rep, 2019,5（1）:34⁃36. doi: 10.1016/j.jdcr.2018.10.016.
［61］	Barnes AC, Blandford AD, Perry JD. Cicatricial ectropion in a patient treated with dupilumab［J］. Am J Ophthalmol Case Rep, 2017,7:120⁃122. doi: 10.1016/j.ajoc.2017.06.017.
［62］	Aszodi N, Thurau S, Seegräber M, et al. Management of dupilumab⁃associated conjunctivitis in atopic dermatitis［J］. J Dtsch Dermatol Ges, 2019,17（5）:488⁃491. doi: 10.1111/ddg. 13809.
［63］	Agnihotri G, Shi K, Lio PA. A clinician′s guide to the recognition and management of dupilumab⁃associated conjunctivitis［J］. Drugs R D, 2019,19（4）:311⁃318. doi: 10. 1007/s40268⁃019⁃00288⁃x.
［64］	Narla S, Silverberg JI, Simpson EL. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis［J］. J Am Acad Dermatol, 2022,86（3）:628⁃636. doi: 10.1016/j.jaad.2021.06.017.
［65］	Blauvelt A, Simpson EL, Tyring SK, et al. Dupilumab does not affect correlates of vaccine⁃induced immunity: a randomized, placebo⁃controlled trial in adults with moderate⁃to⁃severe atopic dermatitis［J］. J Am Acad Dermatol, 2019,80（1）:158⁃167.e1. doi: 10.1016/j.jaad.2018.07.048.
［66］	Martinez⁃Cabriales SA, Kirchhof MG, Constantinescu CM, et al. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: a consensus meeting, 2020［J］. Am J Clin Dermatol, 2021,22（4）:443⁃455. doi: 10.1007/s40257⁃021⁃00607⁃6.

[1]	Zhao Liuqi, Chen Yan, Chen Danyang, Fan Birao, Wang Rui, Shang Panpan, Chen Xixue, Zhu Xuejun, Wang Mingyue. Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(6): 480-485.
[2]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[3]	Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(6): 508-510.
[4]	Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462.
[5]	Zhang Xiao, Chen Fengming, Liu Lin, Luo Li, Guo Jin, Gao Tianwen, Shi Qiong. Analysis of clinicopathological features and prognosis of 163 cases of stage Ⅰ cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 55(5): 389-394.
[6]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372.
[7]	Li Wei, Yin Huibin. Heterogeneity across skin sites in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 349-352.
[8]	Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303.
[9]	Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298.
[10]	Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology. Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 289-294.
[11]	Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767.
[12]	Wang Xiaowen, Li Ruoyu. Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management [J]. Chinese Journal of Dermatology, 2022, 55(3): 272-275.
[13]	Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212.
[14]	Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2022） [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195.
[15]	Zhang Tingting, Zhu Fengyi, Yang Mei, Zhang Ping, Xia Ping, Zhou Xiaoyong. Clinical efficacy and safety of secukinumab in the treatment of 7 cases of erythrodermic psoriasis [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210644-e20210644.

Treatment of atopic dermatitis with dupilumab: an expert consensus

PDF

Knowledge

Abstract

Cite this article

share this article

References ［66］

Related Articles 15

Metrics

Comments

Recommended 10